We could not find your search for GSK Please try again.
Please check our suggestions as you type in the search box.

What's Missing in This Market

By

Jim Cramer

| May 10, 2013 | 10:40 AM EDT
You can't get away from the need for good yield in an era of commodity inflation.

Buffett's Long-Term, High-Dividend Plays

By

Meena Krishnamsetty

| Apr 30, 2013 | 1:59 PM EDT
Let's look at five holdings that stayed in his portfolio for at least a year.
Cramer Talks Abbott & Glaxo

Cramer Talks Abbott & Glaxo

By

Jim Cramer

Apr 17, 2013 | 3:15 PM EDT

The Biotech Revaluation Is On

By

Jim Cramer

| Apr 17, 2013 | 6:20 AM EDT
These four names in particular have made some stunning moves.
Mad Money Uncovered: Merck and the Pharma Laggards

Mad Money Uncovered: Merck and the Pharma Laggards

By

Jim Cramer

Apr 15, 2013 | 12:13 PM EDT

Mega-Hedge Fund Manager Seth Klarman's Five Best Stock Picks

By

Meena Krishnamsetty

| Feb 01, 2013 | 6:00 PM EST
Klarman's hedge funds' top small-cap picks generate significant alpha.
The Next Big Thing In Biotech: Dynavax

The Next Big Thing In Biotech: Dynavax

By

Adam Feuerstein and Gregg Greenberg

Nov 09, 2012 | 5:30 AM EST
Adam Feuerstein, Sr. Columnist for TheStreet, says Dynavax Technologies is the next big thing to watch in biotech.

A Prescription for Election Fever

By

John Reese

| Oct 18, 2012 | 10:58 AM EDT
Now is the time to pop the pharmaceutical pill and buy.
Bearish
GlaxoSmithKline downgraded at UBS
Aug 28, 2012 | 8:03 AM EDT
GSK downgraded to Neutral from Buy, UBS said. $48.18 price target. Valuation, earnings visibility limit potential for further upside.
They Just Don't Get Glaxo!

They Just Don't Get Glaxo!

By

Marek Fuchs

Jul 03, 2012 | 10:54 AM EDT
Marek Fuchs, senior contributing analyst at TheStreet, talks proportion on Glaxo.

Columnist Conversation / Market Updates

NetApp (NTAP): Storing Up Disappointment
By Chris Laudani
| May 21, 2013
| 5:33 PM EDT
Co misses on revenues. Revenue rose (if you can call it that) 0.8% to $1.7 bin. (I was looking for 1.7% y/y rev growth.)...
Making a late move on NTAP
By Robert Lang
| May 21, 2013
| 3:46 PM EDT
We added a call spread for NTAP here, not as pricey as the move implies, the chart not looking too bad. I like this for...
See all »

Our Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.